Allogene Therapeutics, Inc. (ALLO)

Allogene Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019	2018
Cash & Equivalents	93.45	72.2	183.61	192.8	179.43	93.73
Short-Term Investments	365.54	455.42	283.99	644.56	355.41	366.95
Cash & Cash Equivalents	458.99	527.61	467.59	837.36	534.83	460.68
Cash Growth	-13.01%	12.84%	-44.16%	56.56%	16.10%	-
Other Current Assets	0.13	1.21	3.73	7.77	9.74	7.3
Total Current Assets	459.12	528.82	471.32	845.13	544.58	467.98
Property, Plant & Equipment	163.18	196.43	181.02	160.14	100.94	41.61
Long-Term Investments	3.65	76.47	382.38	207.95	63.21	261.97
Goodwill and Intangibles	0	0	0	0	0.15	0.75
Other Long-Term Assets	16.9	19.86	16.11	14.62	8.92	1.54
Total Long-Term Assets	183.72	292.76	579.51	382.7	173.23	305.87
Total Assets	642.84	821.58	1,051	1,228	717.8	773.86
Accounts Payable	5.9	13.89	10.26	10.39	9.25	12.34
Deferred Revenue	0.09	0.1	0.16	38.99	0	0
Other Current Liabilities	31.1	39.74	37.5	44.94	23.83	17.12
Total Current Liabilities	37.08	53.73	47.91	94.32	33.08	29.46
Other Long-Term Liabilities	93.53	100.97	77.72	53.89	55.7	41.23
Total Long-Term Liabilities	93.53	100.97	77.72	53.89	55.7	41.23
Total Liabilities	130.6	154.7	125.63	148.21	88.78	70.69
Retained Earnings	-1,562.23	-1,234.97	-894.55	-646.34	-396.12	-211.53
Comprehensive Income	-0.96	-9.93	-2.57	0.27	1.15	0.31
Shareholders' Equity	512.23	666.88	925.2	1,080	629.02	703.16
Net Cash / Debt	458.99	527.61	467.59	837.36	534.83	460.68
Net Cash / Debt Growth	-13.01%	12.84%	-44.16%	56.56%	16.10%	-
Net Cash Per Share	2.92	3.69	3.44	6.96	5.29	15.91
Working Capital	422.04	475.1	423.42	750.81	511.5	438.52
Book Value Per Share	3.26	4.66	6.81	8.97	6.22	24.29

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).